Clinical performance of Anyplex™ II HPV28 by human papillomavirus type and viral load in a referral population

1st Author: Baasland I, Romundstad PR, Eide ML, et al. (2019)

Key point:
Human papillomavirus (HPV) infection is the main cause of cervical intraepithelial neoplasia (CIN) and invasive cervical cancer (ICC). More than 200 HPV types have been identified, including approximately 40 that preferentially infect the genital tract. Genital HPV are subdivided into low-risk (LR-HPV) types, which are principally found in non-malignant lesions, and high-risk (HR-HPV) types, which are associated with the development of CIN and ICC. Currently, 12 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) are classified as carcinogenic, and HPV 68 is considered as probably carcinogenic by the International Agency for Research on Cancer (IARC). Molecular detection of these HR-HPV is the key of cervical cancer screening. Recently, a new multiplex real-time PCR kit, Allplex™ HPV28 (Seegene, Korea), has been commercialized. This study aims to evaluate its clinical performance for HPV screening and genotyping in comparison with Anyplex ™ II HPV28 (Seegene, Korea).